Exhibit
10.5


 


THIS
NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN
ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION
MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.


 


NOTWITHSTANDING
ANYTHING HEREIN TO THE CONTRARY, THIS NOTE, THE REPAYMENT OF ALL INDEBTEDNESS EVIDENCED HEREBY AND THE EXERCISE OF ANY RIGHT OR REMEDY
HEREUNDER BY THE HOLDER HEREOF ARE SUBJECT TO THE TERMS AND CONDITIONS SET FORTH IN THAT CERTAIN SUBORDINATION AGREEMENT, DATED ON OR
ABOUT SEPTEMBER 30, 2017, BY AND BETWEEN CROSSROADS FINANCIAL GROUP, LLC AND THE INITIAL HOLDER HEREOF. IN THE EVENT OF ANY CONFLICT
BETWEEN THE TERMS OF SUCH SUBORDINATION AGREEMENT AND THIS NOTE, THE TERMS OF THE SUBORDINATION AGREEMENT SHALL GOVERN AND CONTROL.


 


CONVERTIBLE
SECURED PROMISSORY NOTE


 


	$2,871,967	November
    29, 2020 (the “Effective Date”)
	CPN-4	Los
    Angeles, California


 


For
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, MusclePharm Corporation, a Nevada
corporation (the “Company”), promises to pay to Ryan Drexler or his assigns (the “Holder”)
the principal sum of Two Million, Eight Hundred Seventy-one Thousand, Nine Hundred Sixty-Seven Dollars ($2,871,967), plus interest
on the outstanding principal amount at the rate of twelve percent (12%) per annum, in each case in accordance with the terms and subject
to adjustment as set forth in this note (this “Note”).


 


This
Note is secured by a lien on and security interest in all of the assets and properties of the Company, as described in the Sixth Amended
and Restated Security Agreement of even date herewith by and between the Company and the Holder (the “Security Agreement”).


 


This
Note is subject to the following terms and conditions:


 


1.
Maturity.


 


(a)
Repayment. Unless earlier converted or repaid (as applicable) as provided in Sections 1(d), 2 or 3, all outstanding principal
(including any PIK Interest) and any accrued but unpaid interest under this Note (whether or not that interest has been capitalized)
(the “Conversion Amount”), shall be due and payable on July 1, 2021 (as such date may be accelerated solely in accordance
with the terms hereof, the “Maturity Date”).


 


(b)
Interest.


 


(i)
Interest on this Note shall commence on the Effective Date and shall continue and accrue daily at the applicable rate on the outstanding
principal amount until paid in full or converted in accordance with this Note.


 




    	-1-



    	 



    

 


(ii)
Interest shall be computed on the basis of a year of 365 days for the actual number of days elapsed.


 


(iii)
Accrued and unpaid interest shall be paid by the Company to the Holder in cash on the last day of each calendar quarter (each such date,
an “Interest Payment Date”), provided that, at the irrevocable election of the Company (as determined
by the independent directors of the Board) made in writing by notice to the Holder at least two (2) business days prior to any Interest
Payment Date, and so long as no Event of Default has occurred and is then continuing, the Company may elect to pay the PIK Amount of
such interest either (at the sole option of the independent directors of the Board) (i) in kind by increasing the principal amount of
this Note by such PIK Amount, convertible into shares of the company’s Common Stock .001 par value per (“Common Stock”)
, at the closing price per share on the last business day of such calendar quarter immediately preceding such Interest Payment Date,
rounded down to the nearest whole share on such Interest Payment Date. In no event, shall the conversion price on such PIK Amount be
less than $0.10, or (ii) in shares of the Company’s Common Stock, at the closing price per share on the last business day of such
calendar quarter immediately preceding such Interest Payment Date, rounded down to the nearest whole share on such Interest Payment Date.
The “PIK Amount” shall, in respect of any Interest Payment Date, be an amount equal to one-sixth of the interest otherwise
payable on such Interest Payment Date. Any interest paid in kind by adding such interest then due to the unpaid principal amount shall
be referred to as “PIK Interest.”


 


(iv)
Any interest not paid when due in cash (including any PIK Interest) shall be capitalized and added to the principal amount of this Note
and shall bear interest, compounded annually, along with all other unpaid principal, capitalized interest and other capitalized obligations
hereunder.


 


(c)
Events of Default.


 


(i)
Notwithstanding Section 1(a) above, at the option and upon the declaration of the Holder and upon written notice to the Company, the
entire Conversion Amount shall become due and payable upon an Event of Default. The occurrence of the following shall constitute an “Event
of Default”:


 


(1)
the Company fails to pay any and all unpaid principal, accrued and unpaid interest and all other amounts owing under the Note and
the Security Agreement when due and payable pursuant to the terms of the Note; provided, however, that an Event of Default
shall not be deemed to have occurred on account of a failure to pay due solely to an administrative or operational error of any depositary
institution that is crediting by ACH or wiring such payment if the Company had the funds to make the payment when due and payment is
received by the Holder within two (2) business days following the Company’s knowledge of such failure to pay;


 


(2)
the Company or any of its subsidiaries files any petition or action for relief under any bankruptcy, reorganization, insolvency or
moratorium law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any general assignment
for the benefit of creditors;


 


(3)
an involuntary petition is filed against the Company or any of its subsidiaries (unless such petition is dismissed or discharged
within forty-five (45) days) under any bankruptcy statute or similar law now or hereafter in effect, or a custodian, receiver, trustee,
assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property
of the Company; or


 




    	-2-



    	 



    

 


(4)
the Company breaches any other material term of this Note or the Security Agreement (unless, in the case of any curable material
breach, such material breach is cured within thirty (30) days of the earlier of the date on which (x) the Holder has given notice of
such breach to the Company and (y) the Company has actual knowledge of such breach);


 


(5)
the Company amends or modifies the terms of any existing indebtedness in a manner that increases the principal amount thereof or
the interest rate applicable thereto, accelerates the maturity of the obligations thereunder or otherwise adversely affects the Holder;
provided, that, the foregoing shall not constitute an Event of Default if undertaken, caused, approved or voted in favor
of by the Holder in his capacity as an employee, officer or director of the Company;


 


(6)
a final judgment or judgments for the payment of money aggregating in excess of $100,000 that are not covered by insurance or an
indemnity from a creditworthy party are rendered against the Company and/or any of its subsidiaries and which judgments are not, within
thirty (30) days after the entry thereof, bonded, discharged or stayed pending appeal, or are not discharged within thirty (30) days
after the expiration of such stay;


 


(7)
the Company fails to pay, when due, giving effect to any applicable grace period, any payment with respect to any funded indebtedness
in excess of $100,000 due to any third party (other than, with respect to unsecured funded indebtedness only, payments contested by the
Company in good faith by proper proceedings and with respect to which adequate reserves have been set aside for the payment thereof in
accordance with U.S. generally accepted accounting principles) or is otherwise in breach or violation of any agreement for monies owed
or owing in an amount in excess of $100,000, other than unsecured trade obligations in the ordinary course of business, which breach
or violation permits the other party thereto to declare a default or otherwise accelerate amounts due thereunder; provided, that,
the foregoing shall not constitute an Event of Default if undertaken, caused, approved or voted in favor of by the Holder in his capacity
as an employee, officer or director of the Company; or


 


(8)
there exists any circumstances or events that would, with or without the passage of time or the giving of notice, result in a default
or event of default under any agreement binding the Company or any subsidiary, which default or event of default would or is likely to
have a material adverse effect on the business, assets, operations or financial condition of the Company and its subsidiaries, taken
as a whole; provided, that, the foregoing shall not constitute an Event of Default if such circumstances or events are
undertaken, caused, approved or voted in favor of by the Holder in his capacity as an employee, officer or director of the Company; provided,
however, that all obligations under this Note, including without limitation all principal (including any PIK Interest)
and all accrued and unpaid interest, shall be accelerated, and shall be immediately and automatically due and payable without any notice
to the Company or other action, upon the occurrence of any Event of Default described in clause (2) or (3) of this Section 1(c)(i).


 


(d)
Conversion. The Holder may at any time, and from time to time, in the sole discretion of the Holder, upon written notice to the
Company, elect to convert all or a portion of the Conversion Amount into shares of the Common Stock, at a price per share equal to twenty-
three cents ($0.23), rounded down to the nearest whole share.


 


2.
Mechanics and Effect of Conversion.


 


(a)
Effectiveness of Conversion. Upon conversion of this Note, the Company will be forever released from all of its obligations and
liabilities under this Note with respect to that portion of the Conversion Amount being converted, including without limitation the obligation
to repay such portion of the principal amount and accrued and unpaid interest. Principal and accrued and unpaid interest on this Note
will be converted proportionally unless otherwise specified by the Holder. Upon conversion of this Note, the Company shall take all such
actions as are necessary in order to ensure that the Common Stock issuable with respect to such conversion shall be validly issued, fully
paid and nonassessable.


 




    	-3-



    	 



    

 


(b)
Issuance of Certificates. Upon conversion of this Note, the Holder shall surrender this Note, duly endorsed, at the principal
offices of the Company or any transfer agent of the Company. At its expense, the Company shall, as soon as practicable thereafter, issue
and deliver to such Holder, at such principal office, a certificate or certificates for the number of shares of Common Stock to which
such Holder is entitled upon such conversion, together with any other securities and property to which the Holder is entitled upon such
conversion under the terms of this Note, including a check payable to the Holder for any cash amounts payable as described herein. Upon
any partial conversion of this Note, a new Note containing the same date and provisions of this Note shall, at the request of the Holder,
be issued by the Company to the Holder for the principal balance of this Note and interest which shall not have been converted or paid.


 


(c)
Fractional Shares. No fractional shares of the Company’s Common Stock will be issued upon conversion of this Note. If any
fractional share of Common Stock would, except for the provisions hereof, be deliverable upon conversion of this Note, the Company, in
lieu of delivering such fractional share, shall pay an amount in cash equal to the value of such fractional share, as determined by the
per share conversion price used to effect such conversion.


 


3.
Payment; Prepayment. All payments shall be made in lawful money of the United States of America at such place as the Holder hereof
may from time to time designate in writing to the Company. Payment shall be credited first to any fees and expenses due and payable hereunder,
then to accrued and unpaid interest, and then the remainder shall be applied to principal. The Company may prepay this Note in whole
or in part at any time following at least fifteen (15) and no more than sixty (60) days’ advance written notice to the Holder,
provided that the Holder shall retain all rights of conversion until the date of repayment, notwithstanding the pendency
of any prepayment notice.


 


4.
Adjustment Provisions. If after the Effective Date the Company shall make or issue, or shall fix a record date for the determination
of eligible holders of its capital stock entitled to receive, a dividend or other distribution payable with respect to the Common Stock
that is payable in securities of the Company, assets (including cash), or rights or warrants to purchase shares of Common Stock or securities
convertible into shares of Common Stock (each, a “Dividend Event”), and such dividend or other distribution is actually
made, then, and in each such case, the Holder, upon conversion of all or a portion of the Conversion Amount into shares of Common Stock
at any time after such Dividend Event, shall receive, in addition to the Common Stock issuable upon such conversion of the Note, the
securities or other assets, rights or warrants that would have been issuable to the Holder had the Holder, immediately prior to such
Dividend Event, converted such Conversion Amount into Common Stock.


 


5.
Covenants.


 


(a)
Restrictions on Additional Indebtedness and Liens and Subordination. The Company may not incur or suffer to exist any Indebtedness
(as defined below) other than Permitted Indebtedness (as defined below) or any Lien (as defined below) other than Permitted Liens (as
defined below).


 


(i)
“Indebtedness” shall mean any and all indebtedness for borrowed money; all obligations in respect of any deferred
purchase price; all obligations in respect of capital leases; all reimbursement obligations in respect of letters of credit, surety bonds
and similar instruments; all obligations evidenced by notes, bonds, loan agreements, debentures and similar instruments; and all guarantee
obligations and contingent obligations in respect of any of the foregoing.


 




    	-4-



    	 



    

 


(ii)
“Permitted Indebtedness” shall mean (a) Indebtedness evidenced by this Note; (b) Indebtedness in respect of taxes,
fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings;
provided, that Company maintains adequate reserves therefor; (c) Indebtedness existing as of the date hereof (1) and set
forth on the schedule of Permitted Indebtedness attached hereto, or pursuant to an instrument set forth on such schedule or (2) payable
to the Holder pursuant to another instrument; (d) Indebtedness to trade creditors (including suppliers) incurred in the ordinary course
of business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (e) extensions, refinancings,
repayment and renewals of the obligations under this Note and under any Permitted Indebtedness described in clause (d) above, provided
that the principal amount is not increased or the terms modified to impose materially more burdensome terms upon the Company,
and (f) Subordinated Indebtedness incurred after the date of this Note and approved by a majority of the independent directors of the
Board of Directors of the Company (the “Board”).


 


(iii)
“Subordinated Indebtedness” means secured and/or unsecured Indebtedness expressly subordinated to the obligations
of the Company to the Holder hereunder and under the Security Agreement, including in payment and lien priority.


 


(iv)
“Lien” shall mean any lien, claim, encumbrance or similar interest in or on any asset, including without limitation
any security interest or mortgage.


 


(v)
“Permitted Lien” shall mean (a) Liens pursuant to the Security Agreement, including securing Indebtedness evidenced
by this Note; (b) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested
in good faith by appropriate proceedings, provided that the Company maintains adequate reserves therefor; (c) claims of
materialmen, mechanics, carriers, warehousemen, processors or landlords arising out of operation of law so long as the obligations secured
thereby (i) are not past due or (ii) are being properly contested and for which the Company has established adequate reserves; (d) Liens
consisting of deposits or pledges made in the ordinary course of business in connection with workers’ compensation, unemployment
insurance, social security and similar laws; (e) Liens on equipment (including capital leases) to secure purchase money Indebtedness
existing as of the date hereof, or any permitted refinancing thereof, so long as such security interests do not apply to any property
of the Company other than the equipment so acquired, and the Indebtedness secured thereby does not exceed the cost of such equipment,
and provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing
Lien and the principal amount of the Indebtedness being extended, renewed, or refinanced (as may have been reduced by any payment thereon)
does not increase; (f) Liens on accounts, inventory, machinery, equipment, instruments, documents, chattel paper, general intangibles
and other assets to secure purchase money Indebtedness under agreements set forth on the schedule of Permitted Indebtedness attached
hereto and (g) Liens to secure the obligations under agreements set forth on the schedule of Permitted Liens attached hereto.


 


6.
Transfer; Successors and Assigns. The terms and conditions of this Note shall inure to the benefit of and be binding upon the
respective successors and assigns of the Company and the Holder. Notwithstanding the foregoing, the Holder may not assign, pledge or
otherwise transfer this Note without the prior written consent of the Company. Subject to the preceding sentence, this Note may be transferred
only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument
of transfer in form satisfactory to the Company. Thereupon, a new note for the same principal amount and interest will be issued to,
and registered in the name of, the transferee. Interest and principal are payable only to the registered holder of this Note.


 




    	-5-



    	 



    

 


7.
Governing Law. This Note shall be governed by and construed in accordance with the laws of the State of California (without giving
effect to any conflict of laws principles that would require application of the laws of another jurisdiction).


 


8.
Jurisdiction. Each of the Company and the Holder irrevocably submits to the jurisdiction of the courts of the State of California
and of the United States sitting in the State of California, and of the courts of its own corporate or individual domicile with respect
to actions or proceedings brought against it as a defendant, for purposes of all proceedings. Each of the Company and the Holder irrevocably
waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any proceeding
and any claim that any proceeding has been brought in an inconvenient forum. Any process or summons for purposes of any proceeding may
be served on the Company or the Holder, as applicable, by mailing a copy thereof by registered mail, or a form of mail substantially
equivalent thereto, addressed to it at its address as provided for notices under this Note.


 


9.
Waiver of Jury Trial. Each of the Company and the Holder hereby irrevocably waives any and all right to trial by jury in any proceeding.


 


10.
Notices. Any notice required or permitted by this Note shall be in writing and shall be deemed sufficient when delivered personally
or by overnight courier or sent by email or fax (upon customary confirmation of receipt), or forty-eight (48) hours after being deposited
in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party’s address
or fax number as set forth on the signature page, as subsequently modified by written notice, or if no address is specified on the signature
page, at the most recent address set forth in the Company’s books and records; provided, that, any notice to the Company by the
Holder also shall be provided to the independent directors of the Board.


 


11.
Amendments and Waivers. Any term of this Note may be amended only with the written consent of the Company and the Holder. Any
amendment or waiver effected in accordance herewith shall be binding upon the Company, the Holder and each transferee of this Note.


 


12.
Entire Agreement. This Note, together with the Security Agreement, constitutes the entire agreement between the Company and the
Holder pertaining to the subject matter hereof, and any and all other written or oral agreements existing between the Company and the
Holder are expressly canceled.


 


13.
Counterparts. This Note may be executed in any number of counterparts, each of which will be deemed to be an original and all
of which together will constitute a single agreement.


 


14.
Action to Collect on Note. The Company promises to pay all costs and expenses, including reasonable attorney’s fees, incurred
in connection with the collection or enforcement of this Note or any obligation hereunder, including without limitation during or in
the context of any bankruptcy, receivership, trusteeship, reorganization or insolvency proceeding or other proceeding under any other
law for the relief of, or relating to, debtors, now or hereafter in effect, and all such amounts shall be payable on demand (or, if the
Holder is prevented by applicable law from making demand, as and when incurred by the Holder) and, if not paid when due, shall be capitalized
and become part of the principal amount of this Note, and interest shall accrue thereon as set forth for other principal amounts under
this Note.


 


15.
Loss of Note. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this
Note or any Note exchanged for it, and indemnity satisfactory to the Company (in case of loss, theft or destruction) or surrender and
cancellation of such Note (in the case of mutilation), the Company will make and deliver in lieu of such Note a new Note of like tenor.


 




    	-6-



    	 



    

 


16.
Interest Rate Limitation. Notwithstanding anything to the contrary contained herein, the interest paid or agreed to be paid under
this Note shall not exceed the maximum rate of non-usurious interest permitted by applicable law (the “Maximum Rate”).
If the Holder shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal
amount remaining owed under this Note or, if it exceeds such unpaid principal amount, refunded to the Company. In determining whether
the interest contracted for, charged, or received by the Holder exceeds the Maximum Rate, the Holder may, to the extent permitted by
applicable law, (i) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (ii) exclude
voluntary prepayments and the effects thereof, and (iii) amortize, prorate, allocate and spread in equal or unequal parts the total amount
of interest throughout the contemplated term of this Note.


 


17.
Indemnification. The Company shall, to the fullest extent permitted by law, indemnify (but only to the extent of and out of Company
assets) the Holder against all reasonable expenses (including reasonable attorneys’ fees), judgments, fines and amounts paid in
settlement actually and reasonably incurred by the Holder in connection with any claim, action, suit or proceeding, whether civil, criminal,
administrative or investigative, before or by any court or any administrative or legislative body or authority, in which the Holder is
involved, as a party or otherwise, or with which the Holder may be threatened, arising in connection with this Note or the Security Agreement
(each, an “Action”), except to the extent the same has been finally adjudicated to constitute fraud, gross negligence
or willful misconduct of the Holder or a breach by the Holder of this Note or the Security Agreement. Promptly after receipt by the Holder
of notice of the commencement or threatened commencement against it of any third party Action, the Holder will notify the Company. The
Company will be entitled to assume the defense of the Action unless the Holder shall have reasonably concluded that a conflict may exist
between the Company and the Holder in conducting the defense of the Action. If the Company assumes the defense of any Action in accordance
with the provisions of this Section, it will not be liable to the Holder for any legal or other expenses subsequently separately incurred
by the Holder in connection with the defense of such Action. The Company shall not be liable for any settlement of a third-party Action
effected without its written consent, which consent may not be unreasonably withheld.


 


18.
Severability. In the event that any provision of this Note is invalid or unenforceable under any applicable statute or rule of
law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity
or enforceability of any other provision of this Note.


 


[Remainder
of Page Intentionally Left Blank]


 




    	-7-



    	 



    

 


IN
WITNESS WHEREOF, the undersigned have duly executed this Convertible Secured Promissory Note as of the date indicated herein.


 


	 	 	MusclePharm
    Corporation
	 	 	 	 
	 	 	By:	 
	 	 	Name: 	Allen Sciarillo
	 	 	Title:	Chief Financial Officer
	 	 	 	 
	Acknowledged
    and Agreed:	 	 	 
	 	 	 	 
	Ryan
    Drexler	 	 	 
	 	 	 	 
	 	 	 	 


 




    	 



    	 



    

 


Schedule
of Permitted Indebtedness


 


Purchase
and Sale Agreement, dated as of January 11, 2016, between the Company and Prestige Capital Corporation, as amended or modified through
the date hereof, and as hereafter amended or modified with the consent of the Holder in his capacity as such or as a director or officer
of the Company, providing for aggregate borrowings up to a maximum principal amount of $12,000,000 (as amended).


 


Capital
leases outstanding at September 30, 2020 described in Note 6 to the Consolidated Financial Statements contained in the Company’s
Form 10-Q for the quarterly period ended September 30, 2020.


 


Amounts
payable under the Settlement Agreement, dated as of September 25, 2020, between the Company and NBF Holdings Canada Inc.


 


Schedule
of Permitted Liens


 


Loan
and Security Agreement, dated as of October 6, 2017, among the Company, Canada MusclePharm Enterprises Corp. and Crossroads Financial
Group, LLC, as amended or modified through the date hereof, and as hereafter amended or modified with the consent of the Holder in his
capacity as such or as a director or officer of the Company, providing for aggregate borrowings up to a maximum principal amount of $4,000,000
(as amended).


 




    	 



    	 



    

 


AMENDMENT
TO


CONVERTIBLE
SECURED PROMISSORY NOTE


 


THIS
AMENDMENT TO CONVERTIBLE SECURED PROMISSORY NOTE, dated as of August 13, 2021 (this “Amendment”), is made between
MusclePharm Corporation, a Nevada corporation (the “Company”) and Ryan Drexler (the “Holder”;
together with the Company, the “Parties”).


 


WHEREAS,
on November 29, 2020, the Company issued to the Holder a convertible secured promissory note (the “Existing Note”
and, as amended by this Amendment, the “Note”), $2,871,967 of which is outstanding as of the date hereof (the “Effective
Date”); and


 


WHEREAS,
the Parties desire to amend the terms of the Existing Note to extend the Maturity Date (as defined in the Existing Note) to July 14,
2022.


 


NOW,
THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:


 


1.
Amendment to Existing Note.


 


Section
1(a) of the Existing Note is hereby amended and restated in its entirety as follows:


 


“Unless
earlier converted or repaid (as applicable) as provided in Sections 1(d), 2 or 3, all outstanding principal (including any PIK Interest)
and any accrued but unpaid interest under this Note (whether or not that interest has been capitalized) (the “Conversion Amount”),
shall be due and payable on July 14, 2022 (as such date may be accelerated solely in accordance with the terms hereof, the “Maturity
Date”).”


 


2.
Effect of Amendment. From and after the Effective Date, all references to the Existing Note set forth therein or in any other
agreement or instrument shall, unless otherwise specifically provided, be references to the Note as amended by this Amendment and as
may be further amended, modified, restated or supplemented from time to time. This Amendment is limited as specified and shall not constitute
or be deemed to constitute an amendment, modification or waiver of any provision of the Note except as expressly set forth herein. Nothing
herein shall be deemed to entitle the Company or the Holder to a consent to, or a waiver, amendment, modification or other change of,
any of the terms, conditions, obligations, covenants or agreements contained in the Note in similar or different circumstances.


 


3.
Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of California (without
giving effect to any conflict of laws principles that would require application of the laws of another jurisdiction).


 


4.
Jurisdiction. Each of the Company and the Holder irrevocably submits to the jurisdiction of the courts of the State of California
and of the United States sitting in the State of California, and of the courts of its own corporate or individual domicile with respect
to actions or proceedings brought against it as a defendant, for purposes of all proceedings. Each of the Company and the Holder irrevocably
waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any proceeding
and any claim that any proceeding has been brought in an inconvenient forum. Any process or summons for purposes of any proceeding may
be served on the Company or the Holder, as applicable, by mailing a copy thereof by registered mail, or a form of mail substantially
equivalent thereto, addressed to it at its address as provided for notices under the Note.


 


5.
Waiver of Jury Trial. Each of the Company and the Holder hereby irrevocably waives any and all right to trial by jury in any
proceeding.


 


6.
Severability. In the event that any provision of this Amendment is invalid or unenforceable under any applicable statute or rule
of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to
conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision of this Amendment.


 


7.
Counterparts. This Amendment may be executed in any number of counterparts, each of which will be deemed to be an original and
all of which together will constitute a single agreement.


 


[the
remainder of this page left blank intentionally]


 




    	2



    	 



    

 


IN
WITNESS WHEREOF, the Parties have caused this Amendment to Convertible Secured Promissory Note to be executed by their duly authorized
officers as of the date first above written.


 


	 	 	MusclePharm
    Corporation
	 	 	 
	 	 	By:	 
	 	 	Name: 	Sabina
    Rizvi
	 	 	Title:	President
    and Chief Financial Officer
	 	 	 	 
	Acknowledged
    and Agreed:	 	 	 
	 	 	 	 
	Ryan
    Drexler	 	 	 
	 	 	 	 
	 	 	 	 


 




    	3



    	 



    

 


AMENDMENT
NO. 2 TO


CONVERTIBLE
PROMISSORY NOTE


 


THIS
AMENDMENT NO. 2 (this “Amendment”) TO THE CONVERTIBLE SECURED PROMISSORY NOTE, dated as of June 10, 2022
(this “Effective Date”), is made between MusclePharm Corporation, a Nevada corporation (the “Company”),
and Ryan Drexler (the “Holder” and together with the Company, the “Parties”). All capitalized terms
used herein but not otherwise defined shall have the meanings set forth in the Note (as defined herein).


 


WHEREAS,
on November 29, 2020, the Company issued the Holder a convertible secured promissory note in the principal amount of $2,871,967 (as amended
on August 13, 2021, the “Note”); and


 


WHEREAS,
the Parties desire to amend the terms of the Note to extend the Maturity Date as set forth herein.


 


NOW,
THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:


 


	1.	Amendment
    to Maturity Date. Section 1(a) of the Note is hereby amended and restated in its entirety as follows:


 


Repayment.
Unless earlier converted or repaid (as applicable) as provided in Sections 1(d), 2 or 3, all outstanding principal (including any PIK
Interest) and any accrued but unpaid interest under this Note (whether or not that interest has been capitalized) (the “Conversion
Amount”), shall be due and payable on June 10, 2025 (as such date may be accelerated solely in accordance with the terms hereof,
the “Maturity Date”).


 


	2.	Effect
    of Amendment. From and after the Effective Date, all references to the Existing Note set forth therein or in any other agreement
    or instrument shall, unless otherwise specifically provided, be references to the Note as amended, including by this Amendment, and
    as may be further amended, modified, restated or supplemented from time to time. This Amendment is limited as specified and shall
    not constitute or be deemed to constitute an amendment, modification or waiver of any provision of the Note except as expressly set
    forth herein. Nothing herein shall be deemed to entitle the Company or the Holder to a consent to, or a waiver, amendment, modification
    or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Note in similar or different
    circumstances.


 


	3.	Governing
    Law. This Amendment shall be governed by and construed in accordance with the laws of the State of California (without giving
    effect to any conflict of laws principles that would require application of the laws of another jurisdiction).


 


	4.	Jurisdiction.
    Each of the Company and the Holder irrevocably submits to the jurisdiction of the courts of the State of California and of the United
    States sitting in the State of California with respect to actions or proceedings brought against it as a defendant, for purposes
    of all proceedings. Each of the Company and the Holder irrevocably waives, to the fullest extent permitted by law, any objection
    which it may now or hereafter have to the laying of venue of any proceeding and any claim that any proceeding has been brought in
    an inconvenient forum. Any process or summons for purposes of any proceeding may be served on the Company or the Holder, as applicable,
    by mailing a copy thereof by registered mail, or a form of mail substantially equivalent thereto, addressed to it at its address
    as provided for notices under the Note.


 


	5.	Waiver
    of Jury Trial. Each of the Company and the Holder hereby irrevocably waives any and all right to trial by jury in any proceeding.
	 	 
	6.	Severability.
    In the event that any provision of this Amendment is invalid or unenforceable under any applicable statute or rule of law, then such
    provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such
    statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or
    enforceability of any other provision of this Amendment.
	 	 
	7.	Counterparts.
    This Amendment may be executed in any number of counterparts, each of which will be deemed to be an original and all of which together
    will constitute a single agreement.


 


[Signature
Page Follows]


 




    	4



    	 



    

 


IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized signatories as of the
date first indicated above.


 


	 	MUSCLEPHARM
    CORPORATION
	 	 	 
	 	By:	                               
	 	Name: 	Sabina
    Rizvi
	 	Title:	President
    and Chief Financial Officer
	 	 	 
	 	HOLDER
	 	 	 
	 	 
	 	Ryan
    Drexler


 




    	5